Abstract: Methods, systems, and devices for wireless communication are described. In some wireless communications systems, a user equipment (UE) may support two or more uplink switching periods for transmit chain switching. The UE may transmit a UE capability message indicating the UE capability to support a first uplink switching period and a second uplink switching period for transmit chain switching. The first uplink switching period and the second uplink switching period may each correspond to different switching periods associated with configuration switches between different transmit chain configurations of the UE. The UE and a base station may select an uplink switching period from among the first uplink switching period and the second uplink switching period. The UE may transmit an uplink data message to the base station after a preparation time that is based on the uplink switching period.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: A method and apparatus for forming tungsten features in semiconductor devices is provided. The method includes exposing a top opening of a feature formed in a substrate to a physical vapor deposition (PVD) process to deposit a tungsten liner layer within the feature. The PVD process is performed in a first processing region of a first processing chamber and the tungsten liner layer forms an overhang portion, which partially obstructs the top opening of the feature. The substrate is transferred from the first processing region of the first processing chamber to a second processing region of a second processing chamber without breaking vacuum. The overhang portion is exposed to nitrogen-containing radicals in the second processing region to inhibit subsequent growth of tungsten along the overhang portion. The feature is exposed to a tungsten-containing precursor gas to form a tungsten fill layer over the tungsten liner layer within the feature.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive configuration information that indicates an uplink transmit switching configuration for performing uplink transmit switching between a first component carrier and a second component carrier and a sounding reference signal (SRS) carrier switching configuration for performing SRS carrier switching between the second component carrier and a third component carrier, wherein the configuration information is associated with a maximum number of allowable switches over an amount of time. The UE may transmit, based at least in part on the configuration information, one or more signals associated with performing at least one of uplink transmit switching or SRS carrier switching. Numerous other aspects are described.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment may receive, from a first base station associated with a first operator, a broadcast transmission conveying a first portion of a communication; and may receive, without triggering a retransmission of the broadcast transmission, a second portion of the communication via a unicast transmission from a second base station associated with a second operator. Numerous other aspects are provided.

Abstract: Aspects described herein relate to managing and/or configuring, for a user equipment (UE), unicast and/or multicast radio bearers for unicast and/or multicast cells based on measurement reports generated by the UE.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure relates to methods and devices for wireless communication including an apparatus, e.g., a UE and/or one or more networks. In one aspect, the apparatus receives an MBMS video streaming service through broadcast from a first network. In addition, the apparatus determines a failure in association with the reception of the broadcasted MBMS video streaming service. Further, the apparatus receives, based on the determined failure of the broadcasted MBMS video streaming service, the MBMS video streaming service through unicast from a second network. In one configuration, the apparatus transmits information to the second network indicating that the MBMS video streaming service through broadcast from the first network has failed. In such a configuration, the MBMS video streaming service through unicast from the second network is received based on the transmitted information.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Abstract: Certain aspects of the subject matter described in this disclosure can be implemented in a method for wireless communication by a user equipment (UE). The method generally includes receiving a public warning system (PWS) message, wherein the PWS message includes information associated with at least one program provided via a multimedia service, and retrieving the at least one program via the multimedia service based on the information indicated in the PWS message.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Abstract: A reference signal periodically transmitted by a base station in a wireless network can have certain proprietary properties to help prevent detection and utilization of the signal for unauthorized positioning of mobile devices. More specifically, a network node can obscure and introduce time-variation in mapping between positioning signals and a corresponding physical base stations. The network node may also introduce time variations in fields of a base station almanac (BSA) provided to subscribing user equipments (UEs). The information transmitted to the subscribing UEs may be encrypted.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).